It is now 30 years since the first report of a potent zinc-dependent histone deacetylase
(HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory …

Type 1 and type 2 diabetes are characterized by chronic inflammation; both diseases
involve pancreatic islet inflammation, while systemic low-grade inflammation is a feature of …

Epigenetic drug discovery field has evidenced significant advancement in the recent times.
A plethora of small molecule inhibitors have progressed to clinical stage investigations and …

Exercise induces beneficial responses in the brain, which is accompanied by an increase in
BDNF, a trophic factor associated with cognitive improvement and the alleviation of …

Pioneering studies performed over the past few decades demonstrate links between
epigenetics and type 2 diabetes mellitus (T2DM), the metabolic disorder with the most …

Somatic mutations in CREBBP occur frequently in B-cell lymphoma. Here, we show that loss
of CREBBP facilitates the development of germinal center (GC)–derived lymphomas in mice …

Abstract Histone deacetylase 3 (HDAC3) is an epigenetic regulator that involves gene
expression, apoptosis, and cell cycle progression, and the overexpression of HDAC3 is …

Dysregulation of histone deacetylases (HDACs) is closely related to tumor development and
progression. As promising anticancer targets, HDACs have gained a great deal of research …

TET2 somatic mutations occur in∼ 10% of diffuse large B-cell lymphomas (DLBCL) but are
of unknown significance. Herein, we show that TET2 is required for the humoral immune …

CREBBP mutations are highly recurrent in B-cell lymphomas and either inactivate its histone
acetyltransferase (HAT) domain or truncate the protein. Herein, we show that these two …